Speaker Profile
Ph.D., CEO, MEDiC Life Sciences
Biography
Kyuho Han is a scientist and entrepreneur with over 20 years of experience in academia and biotech. He pioneered CRISPR functional genomics in 3D solid tumor models, developing a platform for discovering novel cancer biomarkers and targets, with his work featured in Nature in 2020. He co-founded MEDIC Life Sciences, a San Francisco Bay Area company leveraging CRISPR and 3D tumor models for systematic cancer biomarker and target discovery.
Talk
Synthetic Lethal Genetic Signatures to Enable Novel Cancer Therapeutics
MEDiC's MCAT platform, a next-gen CRISPR functional genomics tool using 3D tumors, identifies synthetic lethal genetic signatures for cancer drugs. These multi-biomarker signatures enhance response rates and market viability by identifying patients most likely to benefit, with the potential to revolutionize patient selection for cancer therapies
Clinical & Research Tools Showcase:
MEDiC
MEDiC is a techbio company leveraging next-gen functional genomics and large-scale 3D tumor models to discover novel targets and biomarkers for cancer drugs. Its mission is to decode the cancer genome to transform and streamline drug development, from target identification to clinical applications
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Clinical & Research Tools Showcase will provide a 15-30 minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
